Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to predict who will develop bone marrow cancer

NCT ID NCT07214324

Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people with early blood disorders (MGUS and smoldering myeloma) who are at risk of developing multiple myeloma, a type of bone marrow cancer. Researchers will use advanced genetic and immune testing on blood and bone marrow samples, along with mouth bacteria analysis, to find markers that signal disease progression. The goal is to improve risk prediction and guide future prevention strategies. The study is observational and does not test any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict which patients with early blood disorders will develop multiple myeloma, enabling earlier monitoring or prevention.
What could go wrong
This is an early observational study with only 60 participants, so results may not apply broadly. It does not test any treatment, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with MGUS, SMM, or MM (with or without bone lytic lesions), as well as patient with osteoarthritis undergoing joint surgery (endoprosthesis or artroplasty) (Healty Volunteers)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years * Male or female patients * Histologically confirmed diagnosis of MGUS, SMM, or MM according to ESMO 2021 guidelines * Willing and able to provide written informed consent HEALTHY VOLUNTEERS (HV) * Age \>60 years * Diagnosis of osteoarthritis (OA) * Scheduled for hospitalization for surgical treatment of OA (endoprosthesis or arthroplasty) * Willing and able to provide written informed consent Exclusion Criteria: * Patients: * Active current infection * Autoimmune disease * Women of childbearing potential unable to exclude pregnancy * Use of high-dose corticosteroids within the past 7 days, potentially affecting immunome composition Healthy Volunteers: * Prior joint surgery or severe joint deformity * Recent trauma, osteonecrosis, or OA caused by prior/current joint infection * Metabolic disorders * Previous or current cancer diagnosis * Autoimmune diseases (e.g., rheumatoid arthritis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monoclonal gammopathy of undetermined significance (MGUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monoclonal gammopathy of undetermined significance (MGUS) Multiple myeloma (MM) Smoldering multiple myeloma (SMM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Ortopedico Rizzoli IRCCS

    ACTIVE_NOT_RECRUITING

    Bologna, Italy

  • S.C Ematologia - Azienda USL IRCCS di Reggio Emilia

    RECRUITING

    Reggio Emilia, Italy

  • UO Ematologia Azienda Ospedaliero-Universitaria "Policlinico Rodolico San Marco"

    ACTIVE_NOT_RECRUITING

    Catania, Italy

  • UOC di Ematologia, Dipartimento di Oncologia, AOU Policlinico "Paolo Giaccone"

    ACTIVE_NOT_RECRUITING

    Palermo, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.